publications-banner

Information about pipeline products

PublicationView

HER3-DXd
Lung Cancer
Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
Yu HA, Baik C, Kim D-W, et al.
Ann Oncol. 2024;35(5):437-447.
Other/Multi
Breast Cancer
Real-world effectiveness of post-trastuzumab emtansine treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer: A multicenter, matched cohort analysis from the Epidemiology Strategy and Medical Economics database (2008-2018)
Courtinard C, Barbet V, Schiappa R, et al.
ESMO RW. 2024. Vol 4. doi: 10.1016/j.esmorw.2024.100043.
Edoxaban
Cardiovascular - VTE
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study
Sueta D, Yamashita Y, Morimoto T, et al.
Thromb Res. 2024;235:P107-115.
Edoxaban
Cardiovascular - AF
Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: Patient characteristics from the prospective observational ETNA-AF-China registry
Guo X, Du J, Yang Y, et al.
Sci Rep. 2024;14:2278.
Edoxaban
Cardiovascular - AF
Outcomes after TAVI in patients with atrial fibrillation and a history of recent PCI: Results from the ENVISAGE-TAVI AF trial
Moreno R, Souza J, Smolnik R, et al.
Clin Res Cardiol. 2024 Jan 31. Epub ahead of print.
Quizartinib
Hematology
Safety and pharmacokinetics of quizartinib combination therapy with standard induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia: Results from two phase 1 trials in Japan and China.
Qi J, Choi I, Ota S, et al.
Clin Pharmacol Drug Dev. 2024;13(5):560-571.
T-DXd
Other/Multi
Unveiling the intra-tumor fate of trastuzumab deruxtecan in a xenograft model to support its mechanism of action
Nagai Y, Oitate M, Shibayama T, Takakusa H, Watanabe N
Drug Metab Pharmacokinet. 2024;56:101001.
T-DXd
Breast Cancer
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: A phase II study protocol (SHAMROCK study)
Dowling GP, Toomey S, Bredin P, et al.
BMC Cancer. 2024;24(1):91.
Other/Multi
Lung Cancer
HER2-mutant advanced and/or metastatic non-small-cell lung cancer: A US electronic health records database analysis of clinical characteristics, treatment practice patterns, and outcomes
Waliany S, Neal JW, Engel-Nitz N, et al.
Clin Lung Cancer. 2024;25(4):319-328.
T-DXd
Other/Multi
Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: A pooled analysis of two phase I studies
Takahashi S, Bando H, Kinoshita I, et al.
Jpn J Clin Oncol. 2024;54(4):434-443.
Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  

footer